The latest addition to the structure has been recently approved by the US Food and Drug Administration ( FDA ) commonly administered under the name of Zepbound™ (Tirzepatide) for the treatment of type 2 diabetes.
Zepbound™ provides millions the new treatment choice
Diabetes is one of the most common non-communicative diseases that affect people worldwide; the CDC report that more than 34 million people in the United States alone live with type 2 diabetes. Few treatment methods are available in the market, and thus, patient suffers a lot and cannot control the blood sugar levels and the side effects related to them like heart diseases, kidney issues, and nerve disorders among others.
How Zepbound™ Works
Tirzepatide, therefore, helps in the enhancement of getting signals of natural body response to the control blood sugar levels. It looks like GLP-1 and GIP, which make the pancreas develop more insulin when blood sugar levels are high and also decreases the glucose level from the liver. Both ways seem to enhance the level of insulin sensitivity and reduce the blood glucose concentration in patients with type 2 diabetes.
Read more- Samsung Wearables Festive Discounts
New era in management of Diabetes announced
Which is why the recent approvals of Zepbound™ signify a great leap forward in diabetes management for not only patients and physicians. As the first drug of its type, Tirzepatide shows a way how to enhance the chances of millions of Americans suffering from type 2 diabetes and to finally improve the quality of glucose control.
Conclusion
This gives the health sector in tackling type 2 diabetes a great boost given that the FDA has approved Zepbound™ (Tirzepatide) for use. With Tirzepatide being the first medication that potentiates both GLP-1 and GIP receptors, it paves the way to more effective treatment of the millions of people affected by this long-term chronic disease. Click here for the source
